Trial of intraoperative cell salvage versus transfusion in ovarian cancer (TIC TOC): Protocol for a randomised controlled feasibility study

BMJ Open

Volumn 8, Issue 11, 2018, Pages

  Galaal, Khadra ^a   Lopes, Alberto ^b   Pritchard, Colin ^a   Barton, Andrew ^c   Wingham, Jennifer ^a   Marques, Elsa M R ^d   Faulds, John ^a   Palmer, Joanne ^a   Vickery, Patricia Jane ^e   Ralph, Catherine ^a   Ferreira, Nicole ^a   Ewings, Paul ^c  

^a ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c Peninsula Schools of Medicine and Dentistry   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

cytoreductive surgery; donor blood transfusion; feasibility trial; intraoperative cell salvage; ovarian cancer; quality of life

Indexed keywords

ADULT; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOREDUCTIVE SURGERY; ECONOMIC EVALUATION; EORTC QLQ OV28 QUESTIONNAIRE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS 5 LEVEL QUESTIONNAIRE; EXPERIENCE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPERATIVE BLOOD LOSS; OVARY CANCER; PATIENT MONITORING; PATIENT PARTICIPATION; POSTOPERATIVE PERIOD; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESOURCE MANAGEMENT; TELEPHONE INTERVIEW; ALLOTRANSPLANTATION; BLOOD AUTOTRANSFUSION; BLOOD SALVAGE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; OVARIECTOMY; OVARY TUMOR; PROCEDURES;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; COST-BENEFIT ANALYSIS; CYTOREDUCTION SURGICAL PROCEDURES; FEASIBILITY STUDIES; FEMALE; HUMANS; OPERATIVE BLOOD SALVAGE; OVARIAN NEOPLASMS; OVARIECTOMY; QUALITATIVE RESEARCH; QUALITY OF LIFE; TRANSPLANTATION, HOMOLOGOUS;

EID: 85056071422     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2018-024108     Document Type: Article

References (49)

1. Cancer Research UK, 2014. Ovarian cancer incidence statistics. http://www.cancerresearchuk.org/cancer
2. National Cancer Intelligence Network (NCIN). Overview of ovarian cancer in england: incidence, mortality and survival. trent cancer registry november 2012. 2012.
3. Schwartz PE. Cytoreductive surgery in the management of ovarian cancer. Oncology 2008;22:1025-33.
4. Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119:259-64.
5. Prescott LS, Aloia TA, Brown AJ, et al. Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol 2015;136:65-70.
6. Warner LL, Dowdy SC, Martin JR, et al. The impact of perioperative packed red blood cell transfusion on survival in epithelial ovarian cancer. Int J Gynecol Cancer 2013;23:1612-9.
7. Ferraris VA, Davenport DL, Saha SP, et al. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. Arch Surg 2012;147:49-55.
8. Watt A, Thomas D, Cohen H, et al. The 2012 annual SHOT Report, 2013.
9. Blajchman MA, Vamvakas EC. "TransfusioN-related immunomodulation." Practical transfusion medicine. 3rd edn, 2009:98-106.
10. Goubran H, Sheridan D, Radosevic J, et al. Transfusion-related immunomodulation and cancer. Transfus Apher Sci 2017;56:336-40.
11. Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia. Br J Anaesth 2010;105:401-16.
12. The Association of Anaesthetists of Great Britain and Ireland (AAGBI). The Association of Anaesthetists of Great Britain and Ireland (AAGBI) Safety guideline-blood transfusion and the anaesthetist: intra-operative cell salvage, 2009.
13. Krajewski K, Ashley RK, Pung N, et al. Successful blood conservation during craniosynostotic correction with dual therapy using procrit and cell saver. J Craniofac Surg 2008;19:101-5.
14. Bridgens JP, Evans CR, Dobson PMS, et al. Intraoperative red bloodcell salvage in revision hip surgery. The Journal of Bone & Joint Surgery 2007;89:270-5.
15. Colwell CW, Beutler E, West C, et al. Erythrocyte viability in blood salvaged during total joint arthroplasty with cement. J Bone Joint Surg Am 2002;84-A:23-5.
16. Williamson KR, Taswell HF. Intraoperative blood salvage: a review. Transfusion 1991;31:662-75.
17. Akbulut S, Kayaalp C, Yilmaz M, et al. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. World J Gastroenterol 2013;19:1625-31.
18. Wang G, Bainbridge D, Martin J, et al. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 2009;109:320-30.
19. Marković M, Davidović L, Savić N, et al. Intraoperative cell salvage versus allogeneic transfusion during abdominal aortic surgery: clinical and financial outcomes. Vascular 2009;17:83-92.
20. Breakwell LM, Getty CJ, Dobson P. The efficacy of autologous blood transfusion in bilateral total knee arthroplasty. Knee 2000;7:145-7.
21. DeAndrade D, Waters JH, Triulzi DJ, et al. Very low rate of patientrelated adverse events associated with the use of intraoperative cell salvage. Transfusion 2016;56:2768-72.
22. Hansen EWN, Kneuchel R, Ruschoff J, et al. Tumor calls in blood shed from the surgical field. Arch.Surg 1995;130:387-93.
23. Kumar N, Zaw AS, Kantharajanna SB, et al. Metastatic efficiency of tumour cells can be impaired by intraoperative cell salvage process: truth or conjecture? Transfus Med 2017;27:327-34.
24. Motoyama S, Saito R, Kamata S, et al. Survival advantage of using autologous blood transfusion during surgery for esophageal cancer. Surg Today 2002;32:951-8.
25. Karczewski DM, Lema MJ, Glaves D. The efficiency of an autotransfusion system for tumor cell removal from blood salvaged during cancer surgery. Anesth Analg 1994;78:1131-1135-5.
26. Frühauf NR, Dumpich O, Kaudel CP, et al. Filtration of malignant cells: tumour cell depletion in an ex vivo model using a leukocyte adhesion filter. Perfusion 2001;16 Suppl:51-5.
27. Catling S, Williams S, Freites O, et al. Use of a leucocyte filter to remove tumour cells from intra-operative cell salvage blood. Anaesthesia 2008;63:1332-8.
28. Zaw AS, Bangalore Kantharajanna S, Kumar N. Is Autologous salvaged blood a viable option for patient blood management in oncologic surgery? Transfus Med Rev 2017;31:56-61.
29. Connor JP, Morris PC, Alagoz T, et al. Intraoperative autologous blood collection and autotransfusion in the surgical management of early cancers of the uterine cervix. Obstet Gynecol 1995;86:373-8.
30. Mirhashemi R, Averette HE, Deepika K, et al. The impact of intraoperative autologous blood transfusion during type III radical hysterectomy for early-stage cervical cancer. Am J Obstet Gynecol 1999;181:1310-6. discussion 5-6.
31. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
32. Oefelein MG, Kaul K, Herz B, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol 1996;155:238-42.
33. Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010;2010:1-10.
34. Galaal KBA, Smits A, Lopes AD. Intraoperative cell salvage in surgery for ovarian cancer: time for action. Medical Journal of Obstetrics and Gynecology 2014;2:1035.
35. Society of Gynecologic Oncology, 2014. FIGO ovarian cancer staging. https://www.sgo.org/wp-content/uploads/2012/FIGOOvarian-Cancer-Staging-10.14.pdf
36. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-56.
37. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
38. Green JTN. Qualitative health methods for health research. London: Sage Publications, 2004.
39. Liamputtong PED. Qualitative research methods. 2nd edn. Oxford: Oxford University Press, 2005.
40. Wailoo A HAM, Grimm S. Comparing the EQ-5D-3L and 5L versions. What are the implications for cost effectiveness estimates? NICE Decision Support Unit report 2017, 2017.
41. National Institute for Health and Care Excellence. Position statement on use of the EQ-5D-5L valuation set. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technologyappraisal-guidance/eq5d5l-nice-position-statement.pdf
42. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15.
43. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006:CD005033.
44. Linder BJ, Frank I, Cheville JC, et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013;63:839-45.
45. Harlaar JJ, Gosselink MP, Hop WC, et al. Blood transfusions and prognosis in colorectal cancer: long-term results of a randomized controlled trial. Ann Surg 2012;256:681-6.
46. Spahn DR, Shander A, Hofmann A. The chiasm: transfusion practice versus patient blood management. Best Pract Res Clin Anaesthesiol 2013;27:37-42.
47. Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010:CD001888.
48. Yamaguchi K, Takagi Y, Aoki S, et al. Significant detection of circulating cancer cells in the blood by reverse transcriptasepolymerase chain reaction during colorectal cancer resection. Ann Surg 2000;232:58-65.
49. Yazer MH, Triulzi DJ. Things aren't always as they seem: what the randomized trials of red blood cell transfusion tell us about adverse outcomes (CME). Transfusion 2014;54:3243-6. quiz 2.